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following the first dose of NESP, no other side effects have
been observed over one year of treatment. She continues to
have well-controlled blood pressure. Her hemoglobin concen-
tration has remained stable over one year in the range of 11.0
to 12.5 g/dL despite NESP being injected less frequently than
was rHuEpo.
Patient 2. A 69-year-old man was referred to the Belfast City
Hospital four years ago for management of advanced chronic
renal failure secondary to atherosclerotic renal vascular disease
and hypertension. His medical history also included ischemic
heart disease, coronary artery bypass surgery eight years ear-
lier, and elective abdominal aortic aneurysm repair six months
prior to nephrology referral. Physical examination revealed:
heart rate, 70 beats/min; blood pressure, 160/80 mm Hg; a grade
III/VI mitral systolic murmur; and clear lung fields. No jugular
venous distension was present. Epigastric and femoral artery
CASE PRESENTATION bruits were present and the foot pulses were weak. His medica-
Patient 1. A 41-year-old woman with end-stage renal disease tions included aspirin, dipyridamole, simvastatin, amlodipine,
secondary to chronic pyelonephritis and hypertension com- doxazosin, isosorbide mononitrate, and frusemide. Laboratory
menced hemodialysis three years ago. A forearm arteriovenous data included: hemoglobin, 11.7 g/dL; serum creatinine, 474
fistula had been created eight months prior to start of dialysis. A mol/L (5.4 mg/dL); creatinine clearance, 15 mL/min; and se-
rum total cholesterol, 5 mmol/L. Two months later he had acongenital absence of the sacrum had resulted in a neurogenic
cerebrovascular accident resulting in a left-sided hemiparesisbladder associated with vesico-ureteric reflux and recurrent
from which he made a good functional recovery.urinary tract infections. A colonic conduit had been constructed
Ten months after his original referral, he had reached end-in childhood with no evidence during follow-up of carcinoma
stage renal failure and was admitted for placement of a tunneledin the urinary diversion. The patient had a normochromic nor-
internal jugular vein dialysis catheter. An echocardiograph atmocytic anemia (hemoglobin, 9.3 g/dL) and was iron replete
that time revealed diffuse impairment of left-ventricular func-at the start of dialysis (serum ferritin 100 g/L, transferrin
tion, ejection fraction of 35%, and moderate calcification ofsaturation 20%).
the mitral valve.She was treated with recombinant human erythropoietin
Three months after starting dialysis, he complained of fatigue(rHuEpo) with the aim of achieving a target hemoglobin of
and increased frequency of angina. He had a normochromic 11 g/dL. Intravenous iron saccharate was given once weekly
normocytic anemia (hemoglobin 9.6 g/dL) and was iron repleteto optimize iron stores. Her hemoglobin was maintained in the
(ferritin 100 g/L; transferrin saturation 20%). He was en-range of 11 to 12 g/dL by once-weekly subcutaneous rHuEpo
rolled in a clinical trial of once-weekly intravenous NESP forinjections. She later enrolled in a trial of subcutaneous novel
treatment of renal anemia. The dose was escalated until theerythropoiesis-stimulating protein (NESP) for the manage-
hemoglobin level was within the target range of 11 to 13 g/dL.ment of renal anemia. She was converted from rHuEpo therapy His iron stores have been maintained with intravenous iron
to NESP with a subcutaneous injection given every two weeks. saccharate. He has now been treated with NESP for 33 months
Apart from a transient stinging sensation at the injection site and has not required blood transfusion over this period. He
has remained clinically stable on hemodialysis with only one
admission to hospital for elective arteriovenous fistula con-
The Nephrology Forum is funded in part by grants from Amgen, struction. He has had no apparent side effects related to NESP.
Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo-
rated; and Bristol-Myers Squibb Company.
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Renal Medicine, Queen’s University of Belfast, Northern are similar in normal and uremic individuals [12, 13].
Some studies indicate that the kidney has a role in theIreland): These patients illustrate that therapy with novel
erythropoiesis-stimulating protein (NESP) (darbepoe- elimination of erythropoietin [14, 15] but the liver has
been regarded as the primary site of erythropoietin me-tin alfa, ARANESP, Amgen Inc, Thousand Oaks, CA,
USA) can successfully manage the anemia secondary to tabolism [16]. The major site for elimination of both
endogenous erythropoietin and rHuEpo remains un-chronic renal failure. In the first case, the patient’s ther-
apy was converted from recombinant erythropoietin clear, given reports that in animals removal of the liver
or kidneys does not affect the half-life of erythropoietin(rHuEpo) to less frequent dosing with NESP while ef-
fective control of hemoglobin concentration was main- [17]. In addition, the pharmacokinetics of rHuEpo in
patients with liver cirrhosis are similar to those of normaltained. In the second case, the patient had never received
rHuEpo and was anemic when hemodialysis was initi- individuals [18]. Recent evidence suggests that the bone
marrow is the major erythropoietin elimination pathwayated. The NESP therapy successfully corrected his ane-
mia and during prolonged follow-up has maintained [19].
Human erythropoietin is a glycoprotein with a molecu-the patient’s hemoglobin above the European Best Prac-
tice Guidelines (EBPG) target of 11 g/dL [1] and within lar weight of 30,400 daltons [20]. The molecule consists
of a 165 amino acid polypeptide chain linked by twothe target hematocrit range of 33% to 36% detailed in
the NKF-DOQI guidelines for renal anemia manage- disulfide bonds. Following translation the protein is
heavily glycosylated, with the additional sugar chainsment [2].
The development of rHuEpo and its subsequent wide- accounting for 40% of the mass of the secreted hormone.
The carbohydrate moieties are added to three specificspread use for treating renal anemia is arguably the most
significant advance in clinical nephrology in the last 20 asparagine or N-glycosylation sites (Asn 24, 38 and 83)
and one serine or O-linked site (Ser 126) in both theyears. An effective alternative to rHuEpo, NESP has
now been licensed for treatment of the anemia of chronic natural and recombinant human erythropoietins [21].
Human erythropoietin is an elongated molecule withrenal failure. In this Forum I will describe how knowl-
edge of the structural biology of erythropoietin was cru- structural features of a left-handed 4-helix bundle similar
to other hemopoietic growth factors [22]. The aminocial in the development of NESP and discuss the initial
clinical data supporting its use for the management of acids engaged in receptor binding are at the opposite
end of the molecule to the cluster of four carbohydraterenal anemia. I also will briefly review the search for
alternative molecular therapies to stimulate erythropoie- chains. Each of the N-linked carbohydrate chains can
contain two, three, or four branches tipped by a nega-sis in renal failure.
Erythropoietin is the principal regulator of the process tively charged sugar molecule, sialic acid. The single
O-linked carbohydrate can have as many as two sialicof erythropoiesis, which maintains an optimal circulating
red cell mass for oxygen delivery to the tissues [3]. Under acid residues. All the other sugars within the carbohy-
drate chains are neutral. Endogenous erythropoietinbasal conditions, erythropoietin is present in serum at
picomolar concentrations (0.8 to 4.0 picomoles/L), and molecules therefore have a variable number of sialic
acid residues, to a maximum of 14. Recombinant humanin adults its primary site of synthesis is the kidney. A
homeostatic feedback mechanism links renal oxygen erythropoietin is purified to contain 9 to 14 sialic residues
per molecule [23]. A fuller understanding of the hetero-sensing with erythropoietin production. Erythropoietin
binds to and activates specific receptors on red cell pro- geneity of these carbohydrate structures was crucial to
the subsequent development of novel erythropoiesis-genitors in the bone marrow. Signal transduction via
the erythropoietin receptor prevents apoptosis of these stimulating protein [24–26].
The carbohydrate portions of erythropoietin are es-erythroid cells, permitting their further proliferation and
differentiation into mature erythrocytes [4]. The subse- sential for its biologic activity in vivo [27]. Removal of
sialic acid residues increases activity in vitro but severelyquent increase in red cell mass improves tissue oxygen-
ation and thereby reduces the stimulus for erythropoietin limits activity in vivo presumably because of increased
clearance of the molecule by hepatic asialoglycoproteinproduction.
Opinion is divided regarding both the primary source receptors [16]. The addition of carbohydrate to erythro-
poietin appears to be necessary for both its cellular secre-of erythropoietin and its eventual metabolic fate. In situ
hybridization studies have demonstrated erythropoietin tion and solubility [28, 29]. The in vivo efficacy of isoforms
of recombinant erythropoietin, with variable numbers ofgene expression in renal peritubular and tubular cells
[5–8]. Subsequently transgenic mice models identified sialic acid residues, was tested in normal mice by assess-
ing the effect of repetitive dosing on hematocrit [23]. Aerythropoietin synthesis in renal peritubular, interstitial,
and proximal tubular cells [9–11]. The secreted hormone marked difference in biologic response was noted: the
isoforms with the highest sialic acid content induced theoccupies a volume of distribution equivalent to the
plasma volume, and its circulating half-life and clearance greatest increase in hematocrit.
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Table 1. Biochemical properties of rHuEpo compared to NESPTwo potential mechanisms could account for the
greater activity of the sialic acid-rich isoforms, namely, rHuEpo NESP
increased erythropoietin receptor binding or a longer Up to 14 sialic acids/molecule Up to 22 sialic acids/molecule
3 N-linked carbohydrate 5 N-linked carbohydrateserum half-life. Utilizing a radioreceptor assay, Egrie
chains chainsand Brown examined the relative affinity of different
1 O-linked carbohydrate chain 1 O-linked carbohydrate chain
isoforms for the erythropoietin receptor [23]. Isoforms 165 amino acids 165 amino acids
40% carbohydrate 51% carbohydratewith the lowest sialic acid content had the highest affinity
30,400 daltons 37,100 daltonsfor the receptor. For instance, the relative affinity of the
pI 4.0 pI 3.3
isoform with six sialic residues was sevenfold greater
than the isoform with the maximum 14 sialic acids. Con-
versely, in experiments designed to determine the circu-
lating half-life of various erythropoietin isoforms, the
over a 6-week period [23]. The NESP increased the he-molecules with the highest sialic acid content had much
matocrit by 33.9% compared to an increase of 22.8%slower clearance from the circulation. For comparison,
induced by rHuEpo. The increased activity of NESPthe half-life of the isoform with 14 sialic acid residues
was associated with a prolonged half-life but reducedwas more than threefold longer than the molecule with
erythropoietin receptor binding affinity. This finding was6 sialic acids. Thus, the sialic acid content was directly
consistent with the data obtained in studies of erythro-related to biologic activity through its influence on serum
poietin isoforms that differed in their sialic acid content.half-life and inversely related to receptor affinity. Fur-
thermore, an increase in serum half-life had a greater ef- Intravenous NESP was approximately 3.6-fold more po-
fect on activity in vivo than did decreased receptor affinity. tent than intravenous rHuEpo when administered three
Exploiting this relationship between serum clearance and times weekly. When NESP and rHuEpo were adminis-
the extent of glycosylation of erythropoietin led to the tered once weekly in mice, NESP was approximately 13-
design and development of novel recombinant erythro- fold more potent. In these animal studies, achieving the
poiesis-stimulating molecules. same increase in hematocrit required a higher weekly
dosage of NESP when administered once weekly com-Development of novel erythropoiesis-
pared to thrice weekly. In contrast, the clinical trials ofstimulating protein
NESP revealed no apparent difference between once
A hyperglycosylated analog of rHuEpo in theory weekly and thrice weekly administration in terms of the
should have a much longer circulating half-life than na-
total weekly NESP dosage (abstract; Macdougall et al,tive human erythropoietin. The N-linked carbohydrate
J Am Soc Nephrol 9:A1317, 1998).chains are attached at consensus amino acid sequences
Intravenous rHuEpo treatment given once weekly is(Asn-XXX-Ser/Thr) to the polypeptide portion of eryth-
less efficient compared to the same total weekly doseropoietin [30]. Several novel consensus sequences were
divided thrice weekly [31]. The pharmacokinetics of lessengineered by site-directed mutagenesis of the cloned
frequently administered rHuEpo predict that the plasmahuman erythropoietin gene [23]. It was essential that
level will fall below a threshold for effective erythro-these sequence changes permit the additional glycosyla-
poiesis. Selective hemolysis of young red blood cellstion without significantly disrupting erythropoietin re-
ceptor binding or biologic activity. An additional con- (neocytolysis), because of their relative erythropoietin
cern, which was addressed in the clinical trials of NESP, deficiency, also can be a factor in poor response to once-
was that altering amino acid sequence might introduce weekly intravenous rHuEpo therapy [32].
epitopes into the tertiary structure of an analog, ren- In most published studies, subcutaneous administra-
dering it immunogenic. A 5 N-linked chain analog of tion of rHuEpo is more cost effective than intravenous
erythropoietin, NESP differs in its amino acid sequence administration at the same dosing schedule [33–36]. The
from human erythropoietin at five positions (Ala30Asn, optimal frequency of dosing with subcutaneous rHuEpo
His32Thr, Pro87Val, Trp88Asn, and Pro90Thr). The as- is unclear. In one study, the efficacy of once weekly
paragine residues at positions 30 and 88 provide the subcutaneous rHuEpo was equivalent to that seen with
anchoring points for the two additional N-linked carbo-
a twice or three times weekly regimen [37].hydrate chains. Therefore, NESP is biochemically dis-
tinct from recombinant erythropoietin by virtue of its
Pharmacokinetics of NESP in dialysis patientshigher molecular weight, sialic acid content, and net neg-
Single-dose pharmacokinetic studies of equimolar dosesative charge (Table 1).
of NESP versus rHuEpo were performed in patients onInitially the efficacy of NESP compared with rHuEpo
peritoneal dialysis [38]. Serum levels of NESP and rHuEpowas assessed in vivo by measuring the increase in hema-
tocrit in mice injected with equimolar doses of peptide were determined at regular intervals after injection by
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Fig. 1. Comparison of single-dose intravenous pharmacokinetics of
novel erythropoiesis-stimulating protein (NESP) compared with recom- Fig. 2. Comparison of subcutaneous (SC) and intravenous (IV) phar-
binant human erythropoietin (rHuEPO; Epoetin alfa). Reproduced by macokinetic profiles of NESP. Reproduced by the kind permission of
the kind permission of Lippincott-Williams & Wilkins, from Macdougall Lippincott-Williams & Wilkins from Macdougall et al, J Am Soc
et al, J Am Soc Nephrol 10:2392–2395, 1999. Nephrol 10:2392–2395, 1999.
immunoassay (Fig. 1). The mean half-life of NESP fol- term maintenance of hemoglobin concentration, and
lowing intravenous injection was three times that of conversion from rHuEpo to NESP therapy. Correction
rHuEpo (25.3 vs. 8.5 hours). In addition, the area under of anemia with NESP was studied in patients who had
the curve (AUC) for intravenous NESP was twice that been stabilized on dialysis but who had not been pre-
of intravenous rHuEpo (291 ng/h/mL vs. 131.9 ng/h/mL). viously treated with rHuEpo. Utilizing a dose-escalation
The volume of distribution was similar for NESP (52.4 protocol, two multicenter trials were conducted involv-
mL/kg) and rHuEpo (48.7 mL/kg) and is equivalent to ing hemodialysis and peritoneal dialysis patients, respec-
the plasma volume. As expected, the mean half-life of tively (abstract; Macdougall et al, J Am Soc Nephrol,
NESP administered by subcutaneous injection was longer 9:A1317, 1998). The same total weekly dose of NESP was
at 48.8 hours compared to 25.3 hours for the intravenous administered either once weekly or three times weekly
route (Fig. 2). The serum concentration peaked at 54.1 to hemodialysis patients by intravenous injection or to
hours and the bioavailability of NESP was estimated to peritoneal dialysis patients by subcutaneous injection. A
be 36.9%. The pharmacokinetic data from this first clini- weekly NESP dose of 0.45 g/kg produced mean hemo-
cal study extended the observations in animals, which globin increases of 1.01 g/dL following subcutaneous ad-
predicted that treatment of renal anemia would require ministration and 1.08 g/dL with intravenous injections
less frequent dosing with NESP compared to rHuEpo. after four weeks. Neither the dosing schedule nor the
The longer half-life of subcutaneous NESP reflects the route of administration appeared to influence the eryth-
balance between continued absorption from the subcu- ropoietic response to NESP. This finding differs from
taneous site and its circulating metabolism. The sub- the clinical experience with rHuEpo [36, 46]. In a further
cutaneous half-life of NESP is approximately twice that study, patients with chronic renal failure (creatinine
reported for subcutaneous rHuEpo [31, 39–41]. The bio- clearance 30 mL/min) and anemia (hemoglobin 11
availability of NESP is comparable to that of subcutane- g/dL) who were not undergoing dialysis were random-
ous erythropoietin [42, 43]. Both the site of administra- ized to receive NESP (0.45 g/kg once weekly) or
tion and skin-fold thickness influence the bioavailability rHuEpo (50 IU/kg twice weekly) (abstract; Locatelli et
of rHuEpo [44, 45], although these factors have not been al, J Am Soc Nephrol 11:A1486, 2000). The primary out-
assessed yet for NESP. come was a composite defined as a rise in hemoglobin
Studies of the pharmacokinetic profile of NESP fol- of 1 g/dL and absolute hemoglobin level of 11 g/dL.
lowing chronic intravenous and subcutaneous adminis- A similar erythropoietic response was seen in both
tration disclosed that NESP does not accumulate over treatment groups (93% NESP, 92% rHuEpo), with a
time (abstract; Allon et al, J Am Soc Nephrol 11:A1308, mean hemoglobin rise after 4 weeks of 1.38 g/dL (NESP)
2000; abstract; Lerner et al, J Am Soc Nephrol 11:A1479, and 1.4 g/dL (rHuEpo).
2000). The elimination half-life of intravenous NESP Two studies have evaluated the efficacy of NESP in
remained three times that of intravenous rHuEpo. maintaining hemoglobin levels. The objective was to con-
firm that the hemoglobin concentration would remain
Therapy stable after conversion to NESP even when it was admin-
Initial therapeutic trials have addressed three areas of istered less frequently compared to rHuEpo. In the
North American hemodialysis trial, 507 patients wereinterest to nephrologists: the correction of anemia, long-
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enrolled into a double-blind study (abstract; Nissenson design features of NESP suggest that antibodies are un-
likely to develop. Because NESP is a heavily glycosylatedet al, J Am Soc Nephrol 11:A1326, 2000). Patients were
randomized in a 1:2 ratio to receive intravenous NESP molecule, the carbohydrate chains might act as a barrier
to immune surveillance of the underlying polypeptideonce weekly plus placebo twice weekly or to continue
receiving thrice-weekly intravenous rHuEpo. The NESP structure. The amino acid changes are at sites distal to
the receptor-binding domain. Therefore, any antibodiesdosage was calculated by a conversion formula (1 g
NESP  200 IU rHuEpo) that equates the protein mass induced by these changes should be non-neutralizing.
Carbohydrate chains themselves are rarely immuno-of the two compounds. No statistically significant dif-
ference in hemoglobin concentrations between baseline genic, and all the additional residues on NESP are found
on the N-linked chains of erythropoietin. Patients haveand the evaluation period was detected during weeks 21
through 28. been regularly tested for the development of NESP anti-
bodies in all the clinical trials; none of these antibodiesIn the European/Australian multicenter study, 522 di-
alysis patients (either hemodialysis or peritoneal dialysis) has been detected to date [47].
Several conclusions can be drawn from the clinicalwere randomized in a 2:1 ratio to NESP or to continue
receiving rHuEpo with no change in the route of adminis- trials involving NESP. Once-weekly NESP administra-
tion by either subcutaneous or intravenous injection cantration (abstract; Vanrenterghem et al, J Am Soc Nephrol
10:A1365, 1999). Patients previously receiving twice- or effectively correct renal anemia in both pre-dialysis and
dialysis patients who have not previously been treatedthrice-weekly rHuEpo were converted to once-weekly
NESP. Patients on once-weekly rHuEpo were converted with rHuEpo. When NESP is administered at a dosage
of 0.45 g/kg, the mean rate of rise of hemoglobin hasto NESP once every 2 weeks. No significant changes in
hemoglobin concentration between the groups occurred been within the European Best Practice Guidelines for
anemia management of 1 to 2 g/dL/month [1]. Conver-from baseline to the evaluation period (24 to 32 weeks).
The NESP dosing was similar regardless of the route of sion of dialysis patients from treatment with rHuEpo to
less-frequently administered NESP by the same routeadministration over the course of the study. However,
the weekly dosage of subcutaneous rHuEpo dosage was has not been associated with any significant change in
mean hemoglobin concentrations. A dosage conversionon average 22% lower compared to intravenous rHuEpo
administration. formula of 200 IU rHuEpo  1 g NESP for equivalent
efficacy is supported by the trial data. In contrast to theThe longer term safety and efficacy of NESP in main-
taining hemoglobin concentrations has been evaluated clinical experience with rHuEpo, there is no difference
in the mean weekly NESP dosage requirement whenin a further European/Australian multicenter study that
enrolled 703 dialysis patients who were treated with administered either via the intravenous or subcutaneous
routes.NESP for as long as one year (abstract; Graf et al, J Am
Soc Nephrol 11:A1317, 2000). Again, patients receiving
Future developmentsrHuEpo twice or three times weekly were converted to
once-weekly NESP, and those receiving rHuEpo once The development of NESP from a design concept to
a therapeutic reality has provided nephrologists with aweekly were converted to NESP every 2 weeks. No sig-
nificant change in hemoglobin concentration was found new molecule for treating renal anemia. The increasing
focus on earlier correction of anemia in pre-dialysis pa-from baseline to 36 weeks, and 96% of patients were
managed at a reduced dosage frequency. tients [48–50] and the upward trend in desired and
achieved target hemoglobin concentrations in dialysisData have been presented on more than 1500 patients
who have received NESP and more than 500 who have patients [1, 2, 51, 52] will place additional pressures on
nephrology budgets. The cost and inconvenience ofbeen treated with rHuEpo in comparative controlled
trials. The overall proportion discontinuing treatment chronic parenteral administration of either NESP or
rHuEpo will remain impediments to their wider use.due to adverse events was 4% for rHuEpo and 2% for
NESP. Side effects attributed to NESP included hyper- Alternative novel strategies for augmenting erythro-
poiesis are being explored, including the synthesis oftension and vascular access thrombosis; however, these
sequelae did not correlate with the rate of rise of hemo- erythropoietin mimetic compounds and gene therapy
[53–57]. The erythropoietin receptor is a member of aglobin or the hemoglobin concentration.
One safety concern regarding NESP is the potential super-family of cytokine receptors and possesses an ex-
tracellular ligand-binding domain, transmembrane re-immunogenicity of the molecule, as its sequence differs
at five amino acid positions compared to endogenous gion, and intracellular signaling domain with tyrosine
kinase activity [58–60]. The erythropoietin receptor iserythropoietin. If antibodies to NESP were to develop,
they might be non-neutralizing or neutralizing (render- activated as a homodimer with only a small number of
ligand-receptor contact points, which account for theing NESP ineffective). Both types of antibodies could
also in theory cross-react with erythropoietin. Several bulk of the binding energy [61, 62]. Peptide mimetics of
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erythropoietin have been discovered with agonist activ- Prof. Maxwell: The metabolism of erythropoietin
has been studied by a number of groups [14–18] butity in compounds containing as few as 13 amino acids
[63–66]. However, the major drawback of the peptide there is no consensus on the predominant route of elimi-
nation of rHuEpo. It had been reported that the livermimetics is that they are unlikely to be active if adminis-
tered orally because of their relatively large molecular was the primary site for degradation of erythropoietin
following uptake by asialoglycoprotein receptors [16].weights and instability. Non-peptide molecules, which
mimic erythropoietic factors in vitro, have activation sites Recent evidence suggesting that the bone marrow is the
main site for erythropoietin clearance [19] requires fur-independent of the hormone-binding domain [67, 68]. A
large proportion of erythropoietin receptors naturally ther investigation to define the degradation pathway. At
present the only way to increase the half-life of erythro-exist as homodimers on the cell surface even in the ab-
sence of the ligand erythropoietin [69]. The distal region poietin is by modifying the structure of the molecule
itself by pegylation or adding sialic acid residues.and receptor tyrosines of the erythropoietin receptor
are not essential for erythropoiesis in vivo [70], but the Dr. Peter Conlon (Beaumont Hospital, Dublin, Ire-
land): Weiss and colleagues reported that the same totaltransmembrane domains are critical for signal trans-
duction [71]. Erythropoietin mimetics presumably in- rHuEpo dosage given once weekly was equivalent to
divided doses thrice weekly [37]. What role is there forduce receptor activation by a conformational change in
the homodimer [72]. NESP compared to once-weekly rHuEpo?
Prof. Maxwell: At present that is difficult to answerThe huge potential market for an orally active erythro-
poietin mimetic coupled with the expanding knowledge conclusively. Most of the published literature relating to
the frequency of rHuEpo administration indicates thatof the structural biology of the erythropoietin receptor
will continue to drive the search for these compounds. more frequent dosing is most cost effective compared to
once-weekly injections [31, 33–36]. Conversely, the studyNephrologists, however, now have a therapeutic choice
between two effective recombinant DNA-derived gly- by Weiss and colleagues concluded that the same total
weekly dosage of subcutaneous rHuEpo had equivalentcoproteins, rHuEpo or NESP, for the management of
efficacy whether rHuEpo was given once weekly or inanemia in patients with chronic renal failure.
divided doses two or three times per week [37]. By virtue
of its longer half-life, NESP is a more potent molecule
QUESTIONS AND ANSWERS than rHuEpo. If an equivalent amount (in terms of the
Dr. John T. Harrington (Dean, Tufts University number of molecules) of NESP and rHuEpo were ad-
School of Medicine, Boston, Massachusetts, USA): Peter, ministered once weekly, I would expect NESP to have
thanks for a superb review of NESP. Could you tell the greater efficacy. However, the relative costs and long-
us how the degree of glycosylation of erythropoietin term safety of NESP in the treatment of renal anemia
compares to that of other secreted hormones, such as are not established yet.
insulin? Dr. John Harty (Daisy Hill Hospital, Newry, North-
Prof. Maxwell: Hemopoietic growth factors/hor- ern Ireland): While the Weiss study has demonstrated
mones are secreted as glycoproteins. The expressed pro- no difference in hemoglobin levels despite variation in
teins undergo post-translational modification with the rHuEpo dosing frequency, these observations were in
addition of carbohydrate groups in the cytoplasm prior stable patients. Would you anticipate that in unstable or
to secretion from the cell. The carbohydrate component ill dialysis patients, reduced frequency rHuEpo regimes
of a glycoprotein is essential for its biologic action in are inadequate to maintain hemoglobin, and does NESP
vivo as it prevents rapid clearance of the protein from have the potential to be more advantageous in this set-
the circulation. To produce rHuEpo, the human erythro- ting?
poietin gene is expressed in mammalian cells to ensure Prof. Maxwell: The essence of your question is, will
that the erythropoietin protein is correctly glycosylated NESP be able to maintain erythropoiesis more effec-
following translation. Heavily glycosylated proteins have tively than rHuEpo in hostile environments, for example,
longer circulating half-lives. In contrast, insulin is not in patients with sub-optimal dialysis or in those with
glycosylated and therefore recombinant human insulin chronic inflammatory states. Understandably, these pa-
production is possible via simpler manufacturing pro- tients are usually excluded from clinical trials, so we have
cesses involving bacterial cells (which lack these glycosyl- no evidence that NESP is more effective in ill dialysis
ation pathways). patients. These ill patients are often said to be “resistant”
Dr. Harrington: Are there studies on the bone mar- to rHuEpo, but in practice this resistance might reflect
row erythropoietin elimination pathway? Do we know inhibition of erythropoiesis in the bone marrow that is
enough about it to use that pathway as a method to mediated by pro-inflammatory cytokines and uremic tox-
increase its half-life, that is, by interfering with the degra- ins. It might be that NESP has no advantage over
rHuEpo in this setting.dation process?
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Dr. George Mellotte (St. James Hospital, Dublin): Prof. Maxwell: The equivalent efficacy of intrave-
nous and subcutaneous NESP administration has onlyOne of the concerns with rHuEpo is the need for supra-
physiologic doses of iron. Have you any evidence that been demonstrated in patients receiving once-weekly in-
jections. As the half-life of subcutaneous NESP is almostiron demands are different with NESP?
Prof. Maxwell: I don’t think there is any evidence twice that of intravenous NESP, I would expect that
once the dosing intervals were extended to every twothat iron utilization in NESP-treated patients is funda-
mentally different than that in rHuEpo-treated patients. weeks, the routes of administration would no longer have
equivalent efficacy.The clinical trials were conducted in patients who were
iron replete, and additional intravenous iron was admin- Prof. Francis Muldowney (University College Dub-
lin): Is the increased red cell mass in thyrotoxicosis medi-istered if the serum ferritin values fell below 200 g/L.
The total iron administered per year in NESP-treated ated by erythropoietin?
Prof. Maxwell: There is some evidence that tri-iodo-patients was not compared to a matched group of
rHuEpo-treated patients. thyronine augments erythropoiesis indirectly by stimu-
lating the release of soluble hemopoietic growth factorsDr. Henry Brown (Antrim Area Hospital, Northern
Ireland): Are there any differences in the profiles of from bone marrow leukocytes [75]. This response ap-
pears to be independent of the direct mitogenic actionerythropoietin isoforms with respect to number of sialic
acid residues between healthy and anemic individuals of erythropoietin.
Dr. Liam Plant (Cork University, Cork, Ireland): Canand the potency of rHuEpo in both groups?
Prof. Maxwell: Circulating erythropoietin exists as you speculate as to the mechanism whereby continued
erythropoietin exposure protects young red blood cellsa heterogeneous collection of individual isoforms. When
isolated, these isoforms have between one and 14 sialic from neocytolysis?
Prof. Maxwell: Erythroid progenitor cells requireacid residues per molecule of erythropoietin. Erythro-
poietin isoforms with a higher number of sialic acid erythropoietin for proliferation, differentiation, and con-
tinued viability. Erythropoietin both stimulates mitogen-residues have a longer half-life and are therefore more
potent. A change in the relative proportions of these esis and prevents programmed cell death of these ery-
throid cells. The rapid decrease in red cell mass observedisoforms would be expected to affect the rate of erythro-
poiesis. I am not aware of any investigations demonstra- following descent from high altitude or in astronauts
entering microgravity is associated with suppression ofting that anemic individuals have an isoform profile with
relatively few sialic acid residues per erythropoietin mol- endogenous erythropoietin. Administration of exoge-
nous rHuEpo can prevent the change in red cell massecule.
Dr. Philip Kalra (Hope Hospital, Salford, United [76]. It is difficult to explain the mechanism of destruction
of newly formed erythrocytes, as these cells have alreadyKingdom): You mentioned that erythropoietin increases
hemoglobin by reducing apoptosis of early red cell forms. lost their nucleus and therefore should not be suscept-
ible to apoptosis. Erythropoietin withdrawal might leadIs anything known regarding the molecular mechanism
of this effect? to rapid hemolysis by altering the interaction between
newly formed erythrocytes and reticuloendothelial pha-Prof. Maxwell: Apoptosis is a major component of
normal erythropoiesis, and erythropoietin controls eryth- gocytes [76].
Dr. Con Cronin (Mid-Western Regional Hospital,rocyte production by retarding DNA breakdown, which
in turn permits the survival and differentiation of eryth- Limerick, Ireland): Are you surprised at the incidence
of hypertension with rHuEpo and NESP, bearing in mindroid precursor cells [73]. Knockout studies in mice have
confirmed that the absence of erythropoietin is lethal to the experience with rHuEpo over a decade? Is it a dose
adjustment, red cell mass problem, or a result of otherembryos because of failure of the final stages of erythroid
differentiation. Signal transduction from the erythropoi- alternative independent factors?
Prof. Maxwell: The mechanisms responsible for hy-etin receptor engages several distinct signaling path-
ways with activation of phosphatidylinositol 3-kinase (PI pertension induced by rHuEpo or NESP therapy are not
well understood. Multiple factors can contribute to the3-kinase) [58, 59]. A downstream target of PI 3-kinase,
the serine/threonine protein kinase Akt (protein kinase rise in blood pressure, including rapid increases in hema-
tocrit and red cell mass, increased sensitivity to vasocon-B), has a major anti-apoptotic role in erythropoietin-
stimulated erythroid precursors [74]. strictors, decreased responsiveness to vasodilators, a di-
rect vasopressor effect of erythropoietin, and remodelingDr. Kottarathil Abraham (Beaumont Hospital): At
what point is the equivalence of intravenous and subcuta- of arterial resistance vessels [77]. The incidence of hyper-
tension in NESP-treated patients is similar to that ofneous NESP lost? In other words, would the first patient
described have maintained her hemoglobin level with rHuEpo-treated patients in the clinical trials I discussed.
Prof. Hugh Brady (Mater Misericordiae Hospital,intravenous rather than subcutaneous administration of
NESP every two weeks? Dublin): The Epo receptor is a member of the super-
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family of cytokine receptors. Does high-dose rHuEpo Treatment with NESP could be initiated provided the
ferritin level was 100 g/L and additional intravenousactivate other cytokine receptors? Are these interactions
likely to contribute to its bioactivity profile? iron therapy was provided. In our own hemodialysis unit,
we aim to maintain ferritin levels between 200 and 800Prof. Maxwell: Erythropoietin is highly specific for
its cognate receptor at physiologic concentrations of the g/L with transferrin saturation 20%.
Dr. Damian Fogarty (Antrim Area Hospital, North-hormone [59]. Pharmacologic doses of rHuEpo should
not activate other cytokine receptors because they have ern Ireland): What accounts for the earlier onset of renal
anemia in patients with diabetic nephropathy?specific affinity for other ligands. Indeed, transgenic mice
that overexpress the erythropoietin gene develop eryth- Prof. Maxwell: The perception is that individuals
with diabetic nephropathy develop anemia earlier thanrocytosis but not thrombocytosis or leukocytosis.
Dr. John Donohoe (Beaumont Hospital, Dublin): In other patients with chronic renal disease with compara-
ble glomerular filtration rates. It has been suggested thatchronic renal failure, why is the degree of anemia dis-
crepant from patient to patient or from disease to dis- hyporeninemia is linked to erythropoietin deficiency
[80]. It is difficult to explain it on the basis that diabeticsease? For instance, why do patients with ESRD second-
ary to polycystic kidney disease often have higher have a unique tubulointerstitial pathology that leads to
an earlier decrease in peritubular or tubular cell erythro-hemoglobin levels than patients with other diseases? Is
this due to a quantitative difference in erythropoietin poietin synthesis. The more aggressive use of ACE inhib-
itors and angiotensin II receptor blockers in these pa-production or possibly to a qualitative difference with a
shift in the profile of erythropoietin isoforms toward tients might blunt erythropoiesis, but this hypothesis is
unproven [78].“pauci-sialic acid” types?
Prof. Maxwell: The degree of anemia is primarily Prof. Brian Keogh (Tallagh Hospital, Dublin): Is
there likely to be any innovation in the route of deliveryrelated to the amount of erythropoietin being secreted by
the kidneys. In general, patients with polycystic kidneys of erythropoietin or NESP?
Prof. Maxwell: The bioavailability of rHuEpo orhave higher circulating erythropoietin levels compared
to patients with other chronic renal diseases with equiva- NESP is maximal when administered intravenously, that
is, all of the administered dose enters the circulation.lent glomerular filtration rates. Another factor might be
variation in the use of ACE inhibitors. The hypothesis Subcutaneous administration of these compounds is
more cost-effective since the prolonged half-life of thethat ACE inhibitors interfere with erythropoiesis in
chronic renal failure remains controversial despite wide- compound, reflecting slow absorption from a subcutane-
ous depot, outweighs the lower bioavailability. Adminis-spread use of these drugs for post-renal transplant eryth-
rocytosis [78]. No evidence supports the suggestion that tration by intraperitoneal injection or inhalation is inef-
ficient and not cost-effective. As both NESP and rHuEpodifferent profiles of Epo isoforms exist in distinct renal
diseases. are complex glycoproteins, they are inactivated by diges-
tion following oral administration. In the future it isDr. Donal Redden (Duke University, Durham, North
Carolina, USA): In view of the adverse results from the possible that mimetic compounds that are orally active
will be developed for clinical use.normalization of hematocrit in hemodialysis trial, should
we be similarly cautious with NESP in aggressive anemia Dr. Peter Garrett (Tyrone County Hospital, Omagh,
Northern Ireland): Are any trials in progress that directlymanagement in patients with cardiovascular disease?
Prof. Maxwell: Your excellent question reminds us compare once-weekly subcutaneous rHuEpo versus once-
weekly subcutaneous NESP?of the reported increased mortality in ESRD patients
with cardiac disease when hematocrits were normalized Prof. Maxwell: I am not aware of any reported or
published trial that has analyzed this important question.[79]. The optimal hematocrit for patients with ESRD is
still the subject of debate. I think we should be cautious I believe it is still unproven which compound and dosing
frequency is the most cost-effective.treating anemia in patients with known cardiac disease
irrespective of whether NESP or rHuEpo is the agent Dr. Harrington: Could I ask you a cost-benefit ques-
tion? It seems to me that the practicing nephrologist isused.
Dr. Yvonne O’Meara (Mater Misericordiae Hospital, likely to more interested in the cost of achieving a target
hemoglobin rather than being concerned about the massDublin): What is the definition of iron replete? Do we
need to be more aggressive in managing iron therapy of protein being administered.
Prof. Maxwell: I agree entirely that cost will be theby achieving ferritin values higher than 100 g/L and
transferrin saturation20%, as in the two patients under bottom line for a practicing nephrologist. If, in routine
clinical practice, NESP proves to have a similar safetydiscussion?
Prof. Maxwell: For the reported clinical trials, a pa- profile to rHuEpo, then we need an urgent answer to the
cost-benefit question. A large trial comparing once-weeklytient was defined as being iron replete if the ferritin level
was200g/L and the transferrin saturation was20%. subcutaneous NESP versus once-weekly subcutaneous
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